Gilead stock reversed its early losses Friday as analysts noted encouraging indicators for its newly approved HIV prevention ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...

Return to shareholders -- $1.4 billion was returned to shareholders as of fiscal Q3 2025 through dividends and share repurchases. Anticipated step-up in expenses -- Research and development, as well ...

Ten years ago, the Indiana community of Austin made headlines for its historic HIV outbreak brought on by intravenous drug ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

Researchers used cryo-EM to study how the HIV enzyme integrase arranges in 3D to slip its DNA into the host genome and pack ...

"You know, it's not the best news. But there was other news that could have been a lot worse, you know?" Charlie Sheen said.

Aside from its status as one of the leaders in Lyme disease research, over 60% of the facility's portfolio comprises HIV/AIDS ...

A pioneering opt-out testing programme for HIV, hepatitis B, and hepatitis C in NHS emergency departments has identified thousan ...